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Abstract:
Obscurin, a giant modular cytoskeletal protein, is comprised mostly of tandem
immunoglobulin-like (Ig-like) domains. This architecture allows obscurin to connect distal
targets within the cell. The linkers connecting the Ig domains are usually short (3-4
residues). The physical effect arising from these short linkers is not known; such linkers
may lead to a stiff elongated molecule or, conversely, may lead to a more compact and
dynamic structure. In an effort to better understand how linkers affect obscurin flexibility,
and to better understand the physical underpinnings of this flexibility, here we study the
structure and dynamics of four representative sets of dual obscurin Ig domains using
experimental and computational techniques. We find in all cases tested, tandem obscurin
Ig domains interact at the poles of each domain and tend to stay relatively extended in
solution.

NMR, SAXS and MD simulations reveal that while tandem domains are

elongated, they also bend and flex significantly. By applying this behavior to a simplified
model, it becomes apparent obscurin can link targets more than 200 nm away. However,
as targets get further apart, obscurin begins acting as a spring, and requires progressively
more energy to further elongate.
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Chapter 1
Background:
Obscurin is an extremely large (~970 kDa) human protein.1 Proteins are biological
macromolecules that perform tasks inside of cells: think of them as biological nanobots.
Proteins are long linear polymers of amino acids, which fold and contort into unique
shapes that dictate their function. Obscurin is a cytoskeletal protein, which means it
functions as scaffolding or structural support in cells. Obscurin is found in both muscle
cells and epithelial (skin, breast tissue, intestinal linings, etc.) cells of humans, and is
made up of multiple domains (parts of proteins that are able to function normally when
isolated from the rest of the protein) linked together.2 This molecular structure is similar
to that of a long train (Figure 1-1)3: each domain is a train car, and the linker between the
cars is slightly flexible.
The purpose of the work
described in this thesis is to
determine how obscurin behaves
in the cell by analyzing its flexibility.
Due to its structure and function,
we expect obscurin to also behave
as a force resistor in cells.4 Other
known cytoskeletal force resistors
are similar in structure to obscurin,

Figure 1-1: A train representing the structure of
obscurin. The train cars are similar to the domains
which are linked together in a long chain.

and are known to resist force
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through stretch. The flexibility and behavior of obscurin when stretched is not well
studied. Obscurin studies will provide insights into how our cells use the cytoskeleton to
translate physical force into biochemical signals and resist strain. Our approach is to
examine obscurin very closely outside the cellular milieu.

This provides us with a

simplified model, which we can then extrapolate into the entire cell. Likewise, since
obscurin is so large, we cannot study the entire protein but instead small parts of the
protein that, for a variety of reasons, are likely to be representative of how the rest of the
molecule works. In this way, this work is highly reductive. However, due to the technical
limits of the techniques that we employ, this simplified version of obscurin must be used.
In this introductory chapter, I explain why we study obscurin, why we chose to study the
regions we chose, and how the biochemical techniques we use can provide visual details
and functional clarity to a world that is far too small for even the most powerful microscope
to visualize.
While obscurin is small relative to everyday objects, it is extremely large relative to
many other proteins. The size and nature of obscurin creates many difficulties in isolating
and studying it, due to the fact that traditional protein structure analysis techniques are
not applicable to the whole obscurin protein. NMR is only suitable for proteins less than
30 kDa, X-ray crystallography does not work well with flexible systems, and Cryo-EM
requires pure soluble protein (which thus far precludes studying obscurin). Thus, we use
a reductive approach in studying its flexibility.
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The architecture of obscurin is similar to a long train (Figure 1-1)3. Each train car
represents a single domain, linked together in a long chain. There are different types of
domains in obscurin, but the most common is the immuno-globulin like (Ig) domain. There
are approximately 60 of these Ig domains in the full protein, and they are mostly
connected by short linkers (4-5 amino acids between the domains) (Figure 1-2)5. There
are two types of short linkers, those that contain proline (an amino acid) and those that

Figure 1-2: The architecture of obscurin, the Ig
domains are shown in yellow.
do not. Prior knowledge of proline in protein structures suggests short proline linkers
would be less flexible than short linkers without proline. We chose four sets of dual
domain systems: two with short proline linkers and two short linkers without proline.
These dual domain systems are representative of ~70% of the obscurin molecule (Figure
1-2)5.
Obscurin is known to have both structural and functional roles in cells, and thus it
appears likely that the protein is somehow involved in force resistance. Here, we attempt
to more directly test obscurin’s ability to bend and flex. We used dual domain systems
(two domains and the linker connecting them) to explain the behavior of the entire protein.
Since the domains themselves are functional apart from the rest of obscurin, it is clear
that the results gathered from these dual domain systems can be extrapolated for the
whole obscurin protein. Most of the domains we studied here have previously solved
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structures using nuclear magnetic resonance (NMR). These domains were not entirely
representative of the global obscurin protein (two sets of domains have proline linkers
and one set has non-proline linkers. In order to create a more representative study, the
NMR structure of another domain (to form another set of domains with a non-proline
linker) is necessary.
Nuclear Magnetic Resonance (NMR)
Our lab specializes in protein NMR structure, function, and analysis studies. NMR
is an experimental technique that can be performed on molecules and proteins, which
can show the chemical environment of each atom or amino acid residue in the protein.
When atoms are in different chemical environments, they have different NMR signals that
elucidate structural information. In order to solve a protein structure using NMR, there
are a number of experiments that must be performed. The protein must first be labelled
using

15N

and

13C,

isotopes of nitrogen and carbon that can be recognized by the NMR.

For small molecules, one-dimensional NMR experiments are sufficient. Two and three
dimensional NMR experiments are necessary to completely solve the much larger protein
structure. These dimensions are analogous to a book. One-dimensional experiments
are similar to a word or a line of a page, two-dimensional experiments are similar to an
entire page of text, and three-dimensional experiments are similar to the thickness of the
book. When the protein sample is placed into the NMR, it is subjected to an external
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Figure 1-3: Cartoon model of how nuclei of atoms are affected
by the external magnetic field of an NMR.
magnetic field (Figure 1-3)6.

This magnetic field affects each atom of the sample

differently depending on where they are located in the structure.

One experiment,

heteronuclear single quantum coherence (HSQC), is two dimensional and is similar to a
roadmap for proteins. Each amino acid in the protein has its own peak on the spectrum.
This experiment is used in conjunction with the three-dimensional experiments to
determine which peaks are associated with each amino acid.
In addition to three dimensional experiments, nuclear Overhauser effects (NOEs)
are used to determine a protein structure. NOESYs are experiments that show which
atoms are near each other in the three-dimensional space of the protein structure. This
helps to create an idea of the structure of the protein, because NOEs show which amino
acids are near each other when the protein is fully folded. These experiments allow us
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to assign each amino acid to certain peaks on the NMR spectra, and create an accurate
and high resolution structure (meaning we are highly confident in the positions of each
atom in the structure within a small range) of the protein of interest. Simulated annealing
programs are also used in order to determine the structure of the protein. These computer
programs use the NMR data and assignments to simulate folding the protein into different
conformations, giving violations (if the conformations do not match the NMR data) and
energy values (the average energy value of each atom in the structure calculated from a
forcefield similar to what is described in the MD section). A structure is considered ‘good’
when the programs give very few violations, and all of the conformations agree with one
another.
NMR chemical shift perturbation maps show differences between protein
structures. Differences occurring between the spectra indicate the areas of the proteins
interact. When proteins interact, the chemical environment around their interaction site
is changed, which produces a change in the NMR spectrum. Peaks on the spectra that
overlap indicate that the areas of the proteins to not significantly interact with each other.
Small Angle X-ray Scattering (SAXS)
SAXS is another experimental technique used to determine the conformation of
the dual domains in solution. The protein sample is illuminated by an X-ray beam, the
beam is scattered off of the protein in solution, and this creates a scattered intensity profile
(Figure 1-4)7.

When analyzed, the intensity and scattering of the pattern provide

information
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Figure 1-4: Diagram of how SAXS data is collected. The scattering curve is used to
determine the Rg values for the sample.
about the conformation/orientation of the protein. SAXS data is obtained in reciprocal
space, so a Fourier transform must be performed in order to analyze the data in real
space. This transformation along with a Guinier analysis (a mathematical technique to
analyze SAXS data) provides an Rg value, or a radius of gyration. Since the protein
sample is in solution, this protein exists in many conformations. The Rg value is an
average of all of the conformations of that sample, as it can freely move in solution. The
Rg value is used to find the length of the molecule, and this information helps to elucidate
the average conformation of molecules in solution.
Molecular Dynamics/Steered Molecular Dynamics (MD/SMD)
In addition to the experimental techniques above, we also performed MD and SMD
simulations on the representative constructs. These computational techniques allowed
us to analyze the domains more closely (on an atom by atom basis). MD is a simulation,
or computer model. A protein structure model is placed in an environment full of water
molecules and the simulation predicts how the protein will behave. The program treats
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each chemical bond as a classical spring and uses Newton’s laws of motion to predict
where each atom would be after a small amount of time (2 x 10-15 seconds). After this
initial time step, the program recalculates the location of each atom, and this process
continues until a sufficient amount of time has been reached (generally in the 10-5/10-6
timescale). A forcefield accounts for various forces that molecules would experience,
such as bond stretching, bond bending, bond twisting, and non-bonding terms such as
electrostatic interactions. SMD is similar to MD, but instead of the protein model moving
randomly, SMD samples low-probability states that would be unlikely to occur in MD. In
this case, we simulated what would happen to the dual domains if they were pulled apart
at a constant rate (0.1 m/s). This pulling adds another spring to the system, attached to
both ends of the dual domains. While unlikely to occur in MD, this SMD simulation
represents the type of movement and stretch that obscurin would be subjected to in

Figure 1-5: Diagram of a muscle cell. Obscurin is shown in blue, connecting
the sarcoplasmic reticulum to the contractile apparatus of the muscle. The
sarcoplasmic reticulum can move, and obscurin tethers it.
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muscle cells (Figure 1-5)8. It is easy to imagine how obscurin (blue) would stretch if the
gray areas began to pull apart from each other.
Chapter 1 is a brief overview and explanation of the techniques described in
chapter 2. The next chapter will explain the experimental results in more detail.
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Chapter 2
Introduction
Most cells in the body are subjected to motion, ranging from muscle cells
contracting and relaxing to epithelial cells conforming to body movement.9 Yet cells also
must be physically strong to maintain homeostasis and normal architecture amidst this
strain.10 Giant cytoskeletal proteins are long, chain-like molecules that connect distal
cellular regions and have the capacity to bend and stretch.5,11–13 Thus, these proteins
provide a potential mechanism to assist the cell in its capability to be both flexible and
strong.
The most well known giant cytoskeletal protein is titin. This protein spans from
the Z-disk to the M-band in myocytes, and is mostly comprised of hundreds of
consecutive, individually-folded Ig domains.5 Through a domain unraveling mechanism,
titin acts as a molecular spring, resisting stretch force longitudinally as the muscle cell
overextends.14–17
Obscurin, another giant cytoskeletal protein, has a similar architecture to
titin.5,8 This protein can be found in at least 20 different forms, ranging from 20 kDa to
970 kDa.1 At its longest, the N-terminal two-thirds of the protein is comprised of over 60
tandem Ig and Fibronectin (FnIII)-like domains connected to their neighbors via short
linkers.18 The C-terminus contains multiple signaling domains (i.e. PH, RhoGEF, IQ)18,19
and either an ankyrin binding region (in obscurin A isoforms)20 or kinase domains (in
obscurin B isoforms).21 Obscurin’s multiple functions are closely linked to its complex
subcellular localization.22,23 In skeletal muscles, the ankyrin binding region of obscurin A
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binds to small ankyrin 1 (sAnk1) at the sarcoplasmic reticulum.20,24–26 Ablation of this
interaction reduces sAnk1 levels, which in turn leads to aberrant Ca2+ homeostasis.27–29
Likewise, obscurin interacts with ankyrin-B in the costamere. When this interaction is
disrupted, skeletal muscles experience increased exercise-induced damage due to the
improper assembly of the dystrophin complex.30 Obscurin B binds to and phosphorylates
N-cadherin at the intercalated disk in cardiomyocytes, suggesting that it may modulate
muscle cell adhesion.21

Complementing these membrane-associated interactions,

obscurin binds to the sarcomeric contractile apparatus in several locations.5 The 58th59th obscurin Ig-like domains form a complex with the titin ZIg9 domain at the Z-disk
during development, suggesting obscurin plays a role in myofibrillogenesis.18,28,31–33
Additionally, the N-terminus of obscurin interacts with titin, slow myosin binding protein
C, and myomesin at the M-band, contributing to the M-band lattice assembly, structure,
and strength.34–37 Thus, obscurin forms the only known connection between the muscle
contractile apparatus and the surrounding membrane structures.5,34,38,39

Clinically,

obscurin is linked to breast and colorectal cancers, and obscurin knockdown cells
undergo epithelial-to-mesenchymal transition.40–42 In muscle, specific obscurin mutations
that alter target protein binding are causally linked to hypertrophic cardiomyopathy,
dilated and restricted cardiomyopathy, and muscular dystrophy.38,43–47
In order to better understand both how obscurin exists in solution and responds to
stretch, here we study a series of representative tandem obscurin Ig domains using
structural biology and computation techniques. We find these dual domain constructs are
predominantly extended in solution, yet the domains are also moderately mobile relative
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to each other. This finding led to the question of how these domains could be extended
(suggesting a framework to maintain this conformation) and also flexible (suggesting that
there is not a significant framework present). MD simulations suggest that transient
noncovalent bonds between mobile regions in neighboring domains are largely
responsible for these dual domains being extended yet dynamic.

Results
Implicit in the observation that obscurin links various cellular targets to each other
is the fact that the protein must act as a tether. While obscurin-target interactions in
muscle are increasingly well documented, the conformation and dynamics of the obscurin
region between these anchor points (the tether) are less understood.

5,21,27,34,35,43

Here,

we investigate obscurin’s conformation in solution. In an effort to more easily collect highresolution information about this protein, we utilized a reductive approach and studied a
series of representative obscurin dual-domain systems. The linkers between obscurin
domains can be broadly divided into short linkers containing proline residues (48% of all
obscurin linkers), short linkers with no proline residues (22%), and long linkers (>6
residues) (30%) (Table 2-1).

Previous studies, plus basic biochemistry knowledge,

suggest the proline-containing linkers may be more rigid, and long linkers are almost
certainly more flexible.48 Here we study two constructs with proline-containing linkers and
two constructs with proline-absent linkers to better understand the mobility these short
linkers confer on the obscurin molecule as a whole.
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Table 2-1:
The linker between each human obscurin Ig domain
Numbered Ig domains from obscurin (CAC44768.1)
Linkers- We define the linker as the residue following the last lysine (or arginine) in
one domain to the residue preceding the first lysine (or arginine) in the next domain. These
were all aligned to the Ig34-39 region, and include the final and first residues of the flanking
domains.
Note that in this nomenclature, Ig57, Ig58, and Ig59 are numbered 47, 48, and 49.
Type of Linker
Long
Long
Short proline containing
Short non-proline
containing
Long
Long
Long
Long
Long
Long
Long
Long
Long
Long
Long
Long
Long
Short proline containing
Short non-proline
containing
Short non-proline
containing
Short proline containing
Short non-proline
containing
Short proline containing
Short proline containing
Short non-proline
containing
Short proline containing

Linked
Domains
1-2
2-3
3-4
4-5

Linker Sequence
daeaacaeqaph
dsdaadtasrpgtstaallahlqrrreamraegapasp
repavp
qgnl

5-6
6-7
7-8
8-9
9-10
10-11
11-12
12-13
13-14
14-15
15-16
16-17
17-18
18-19
19-20

saprkppl
vhlapkla
raapgltankp
qglarflh
sepkvvfak
kepkvvfak
tepkmmfak
tepkgvfak
tepkavfak
sepkavfak
aepkvvfak
aepkavfak
aepkvvfak
epqise
aak

20-21

srvvk

21-22
22-23

eapvl
emrqvr

23-24
24-25
25-26

telpvs
kelpvt
eeqsit

26-27

sdipvv
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Short non-proline
containing
Short proline containing
Short non-proline
containing
Short proline containing
Short non-proline
containing
Short non-proline
containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short proline containing
Short non-proline
containing
Short non-proline
containing
Short proline containing
Short proline containing

27-28

earevt

28-29
29-30

rvkpvv
hdlhvg

30-31
31-32

rerpaa
anc

32-33

qgrrvh

33-34
34-35
35-36
36-37
37-38
38-39
39-40
40-41
41-42
42-43
43-44
44-45
45-46
46-47
47-48

tekpsv
harpvr
talpaq
rpmpah
kalpak
ralpar
ralpik
rampsk
ralpar
rapqpv
taapvr
rvprpk
tepevt
rapevt
taknt

48-49

rgwrle

49-50
50-51

lglpd
ppkpv

Multiple solution structures of individual obscurin Ig-like domains are already in the
Protein Data Base (PDB; Table 2-2). Included in this set of structures are many that
connect to neighboring domains via short proline-containing linkers (i.e. Ig34, Ig35, and
Ig36 in full-length obscurin).18 However, only two published structures- Ig58 and Ig59are connected with a non-proline linker.43,44 Therefore, in order to generate a more robust
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data set for studying domain/domain motion, we first solved the solution structure of Ig57,
a domain that connects to Ig58 via a non-proline linker. The heteronuclear single
Table 2-2:
PDB accession numbers of solution structure human obscurin Ig-like domains (from CAC44768)
PDB code
2ENY
2EDF
2EDR
2EDT
2EDW
2EDH
2EDQ
2EDL
2MWC
2N56

Obscurin domain
Ig27
Ig28
Ig34
Ig35
Ig36
Ig37
Ig38
Ig39
Ig58
Ig59

Position
2735-2825
2826-2915
3361-3449
3449-3537
3537-3630
3614-3713
3713-3806
3801-3897
4342-4430
4430-4519

quantum coherence (HSQC) spectrum of Ig57 is well-dispersed, and every backbone
peak was subsequently sequence-specifically assigned (Figure 2-1A). The resulting
solution structure is of high quality, with more than 10 distance restraints per residue and
no violations greater than 0.40 Å (Table 2-3, Figure 2-2). The 20 best structures overlay
well with each other, with a backbone root-mean-square deviation (RMSD) of residues in
the Ig-like fold being 0.681 ± 0.061 Å. The best structure, judged by having the lowest
RMSD, shows Ig57 arranged into a typical Ig-like fold, with its two beta sheets arranged
into a beta sandwich-like fold (Figure 2-1B).
Next, we constructed a series of dual Ig domains. Ig34/35 and Ig35/36 have short prolinecontaining linkers, and Ig57/58 and Ig58/59 have short proline-absent linkers (Figure 2-
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Figure 2-1: Solution structure of Ig57 (residue 4252-4336 of human obscurin).
A) Fully assigned HSQC of Ig57. B) Cartoon of the best Ig 57 structure. Further
structural analysis can be found in Figure S1 and Table 3.
3A).

All of the domains, individually, are fully assigned using multidimensional

heteronuclear Nuclear Magnetic Resonance Spectroscopy (NMR). For each dual domain
system, the resulting HSQC is almost exactly the sum of the individual domain HSQCs
overlaid on top of each other (Figure 2-3B). This indicates the individual domains do not
significantly interact with their neighbor, except at the extreme poles where the linker
connects the two domains (Figure 2-3C). In addition, there was no evidence of peak
splitting in any of the HSQC spectra, indicating these tandem domains are either in a
single conformation, or else are in fast exchange between several different
conformations. In all cases, the linker residues between two domains were exchange-
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broadened out and could not be assigned, regardless of temperature (37 oC, 25 oC, and
10 oC). Additionally, no nuclear Overhauser effect (NOE) correlations were observed
Table 2-3: NMR-derived restraints and statistics of 20 NMR structures of wild-type Ig571
<20>
Best Structure
Rmsd from distance constraints (Å) 2
Total (884)
0.021 ± 0.001
0.018
Intraresidue (250)
0.005 ± 0.003
0.005
Sequential ( |i - j| = 1 ) (250)
0.013 ± 0.004
0.018
Medium range ( 1 < |i - j| < 4 ) (71)
0.031 ± 0.006
0.024
Long range( |i - j| > 4 ) (241)
0.022 ± 0.004
0.014
Hydrogen bonds (72)
0.042 ± 0.007
0.039
Rmsd from exptl dihedral constraints (°)
F,Y (112)
0.525 ± 0.140
0.538
13
Rmsd from exptl C chemical shifts
13Ca (ppm)
1.350 ± 0.04
1.320
13Cb (ppm)
1.740 ± 0.04
1.700
Rmsd from idealized geometry
Bonds (Å)
0.004 ± 0.000
0.004
Angles (°)
0.565 ± 0.017
0.545
Impropers (°)
0.382 ± 0.021
0.342
Lennard-Jones potential energy (kcal/mol) 3
-315 ± 8
-333
4
% most favorable region in the Ramachandran plot 77.6 ± 3.3
72.0
Rmsd of the mean structure (Å) 5
All backbone atoms
0.68 ± 0.06
0.55
All heavy atoms
1.26 ± 0.07
1.11
1

The 20 ensemble structures, <20>, are the results of simulated annealing calculations. The
best structure is the closest to the average structure. The values shown for the <2> are the
mean ± standard deviation.
2
None of the 20 structures has a distance violation > 0.35 Å or a dihedral angle violation of > 5°.
The force constants used in the SA calculations are as follows: 1000 kcal mol −1 Å2 for bond
length, 500 kcal mol−1 rad−2 for angles and improper torsions, 4 kcal mol−1 Å−4 for the quartic
van der Waals (vdw) repulsion term (hard-sphere effective vdw set to 0.8 times their values in
CHARMm parameters), 50 kcal mole−1 Å−2 for experimental distance constraints, 1 kcal
mol−1 Å−2 for distance symmetry constraints, 0.5 kcal mol−1 ppm−2 for the 13C chemical shift
constraints, and 1.0 for the conformational database potential. The force constants (in kcal
Hz−2) used for dipolar coupling restraints is 0.50.
3
Lennard-Jones van der Waals energies were calculated using CHARMm parameters and were
not used in any stage of the structure determination
4
PROCHECK was utilized to generate the Ramachandran plot
5
Backbone calculations include Cα, N, and C′ atoms. Only residues 3–91 are included since no
long-range NOE correlations were observed for residues 1–2 and 92–104 (the expression tag).
24

Figure 2-2: NMR examples of Ig57 experiments. A) NOESY/TOCSY overlay
of A87 in Ig57. B) Backbone walking experiments used to assign Ig57. C)
Secondary structure diagram of Ig57 with visible NOE correlations.
between tandem domains or between domains and their adjoining linkers, supporting the
notion that these domains are dynamic relative to each other, and that all short linkers,
regardless of composition, experience significant intermediate-timescale (µs-ms)
motions.
Due to the paucity of inter-domain NOE correlations, we cannot use traditional
NMR methods to determine the conformation of these dual domains in solution.
Therefore, we attempted two orthogonal techniques to better understand the solution
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Figure 2-3: NMR dual domain construct analysis. A) Each dual domain construct
labeled with the linker sequence and PDB ID. B) HSQC overlay of Ig58 (red), Ig59
(gold), and Ig58/59 (blue). C) Chemical shift perturbation maps of each dual domain
system of obscurin. Residues colored red indicates a significant HN-N chemical shift
change (>2x st. dev) in the dual domain systems compared to the single domains.
Note that the chemical shift changes are randomly distributed around the models,
which suggests that the domains do not significantly interact with each other.
structures of these tandem domain systems: small angle X-ray scattering (SAXS) and
residual dipolar couplings (RDC). Guinier plots of SAXS data (Figure 2-4A, Figures 2-5,
2-6) show all dual domain systems are extended in solution and have similar Rg values
regardless of linker composition (Figure 2-4B). We next fit our SAXS data to an ensemble
of tandem domain models, each with different domain/domain angles (Figure 2-4C). In
all constructs, the models that best fit the experimental data were almost fully extended,
26

Figure 2-4: SAXS analysis of a representative obscurin dual domain construct. A)
Guinier plots of two concentrations of Ig34/35: 1 mg/mL (black) and 3 mg/mL (red).
B) Dimensions of each dual domain system, calculated from the Rg values (Rg =
√(3*Guinier Slope and Dimension = Rg*2) C) The Ig34/35 best fit model (orange)
compared to other models (gray), calculated via MultiFoXS.61 D) Comparison of one
state model fit (orange) and the two state model fit (blue), to Ig 34/35 1 mg/mL
experimental SAXS data (circles).
in agreement with our Guinier analysis. However, the residuals of our best fits were nonrandom in most cases. Therefore, we re-fit the data using a two-state model: one
extended conformation and the other compact (Figure 2-4D and Figure 2-7). These twostate models showed a better fit with the data, suggesting that all constructs are usually,
but not exclusively, extended.

Further fitting of more complex models yielded
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Figure 2-5: Guinier and RDC analysis. A) Zoom in of Guinier regions of Ig34/35 with
labeled Rg at two concentrations: 1 mg/ml (black) and 3 mg/mL (red). B) RDC
experimental data on Ig58/59. C) Using PALES, The fit of each individual domain and
the dual domain of Ig58/59 to experimental RDC data.

Figure 2-6: Guinier plot and Guinier region zoom in for each dual domain system at
two concentrations. A Ig35/36 at 1 mg/mL (black) and 3 mg/mL (red). B) Ig57/58 at
1.2 mg/mL (black) and 1.4 mg/mL (red). C) Ig58/59 at 2.5 mg/mL (black) and 3.0
mg/mL (red).
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Figure 2-7: (Previous page) Comparison of MultiFoXS one state and two state fits to
experimental SAXS data of each dual domain system at two concentrations. A)
Ig34/35 at 3 mg/mL. B) Ig35/36 at 3 mg/mL. C) Ig35/36 at 5 mg/mL. D) Ig57/58 at
1.2 mg/mL. E) Ig57/58 at 1.4 mg/mL. F) Ig58/59 at 2.5 mg/mL. G Ig58/59 at 3 mg/mL.
progressively better fits. As additional evidence of this apparent flexibility, RDC data on
two of the tandem constructs (Ig35/36 and Ig58/59) show while the individual domains fit
the data well, the data cannot be forced to fit any single dual domain model (Figure 25A/B). In sum, for every dual construct we tested, we conclude tandem Ig domains are
relatively extended but can also exist in multiple conformations.
The finding that every tandem dual domain system is both extended yet flexible
seems paradoxical. To address the problem of how these systems can simultaneously
have this kind of structure and flexibility, we require high-resolution information of the
various domain/domain interfaces. However, no NOE measurements exist between any
of these regions. Additionally, this apparent domain/domain flexibility precludes x-ray
crystallography analysis due to the potential of significant crystal packing artifacts.
Therefore, we turned to molecular dynamic simulations (MD) in an attempt to find possible
domain/domain or domain/linker interactions. All subsequent tandem domain models
were first equilibrated for >50 ns, and the angle between the domains in solution was then
measured over an additional 50 nanoseconds in triplicate (Figure 2-8A).

In all

simulations, each of the dual domain systems maintained a relatively extended structure
on average, but the inter-domain angle varied widely, with a maximum change of
orientation ~50-70 degrees. A global examination of these simulations suggests these
extended conformations are the result of steric hindrance between the domains;
neighboring domains with short linkers clash into each other if the angle between them is
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Figure 2-8: Molecular dynamics analysis of dual domain constructs. A) Domain angle
vs time graph. B) Snapshot of the Ig34/35 domain/domain interface, showing likely
interactions between the domains and the linker.
less than ~120 degrees. These elongated but dynamic dual domain systems persist at
least into the microsecond regime (Figure 2-9), and are in excellent agreement with our
experimental data.
Closer examination of these MD trials showed that in all simulations, multiple
residues at the domain poles participate in long-lived, stabilizing interactions with moieties
in the linkers (Figure 2-8B). Once these interactions form, they usually persist for the
duration of the simulation and are largely independent of domain/domain bending. To
study these interactions in more depth, we next performed steered molecular dynamics
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Figure 2-9: Angle between the domains of Ig58/59 calculated from MD over a period
of ~800 ns.
simulations (SMD) on these systems, where the domain termini were moved apart at a
constant velocity of 1 Å/ns. By elongating the dual-domain systems, SMD gives a more
controlled setting to study how these putative inter-domain and domain/linker interactions
respond to bend and stretch. SMD also simulates a physiologically reasonable timescale
of stretch,4,49 and thus gives us insight into how obscurin may respond to stretch in the
cell.
When a slightly bent dual domain system is stretched, the domains first straighten,
yet many of the inter-domain and domain/linker interactions remain intact (Figure 210A/B). This is accompanied by the addition of either no or very little work to the system
(Figure 2-10C). Only after the domains completely straighten does the linker begin to
extend and these interactions begin to break (Figure 2-10D). Thus, these noncovalent
interactions, originating on linker regions or on loops within the Ig domains, are both longlived and flexible. The existence of such flexible interactions explains how dual domain

32

systems can simultaneously be extended and dynamic. Despite each construct having a
different composition, all four sets of dual domain systems displayed this same behavior
(Figure 2-11). As the domains are stretched further, increasingly more work must be
added to the system until individual domains unravel. This kind of work-stretch profile
occurs in all model constructs, and is reminiscent of other well-studied multi-Ig-domain
systems.16,50 These domain-rupturing events present an oft-used cellular mechanism
through which obscurin can resist large stretch forces.17
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Figure 2-10: Representative steered molecular dynamics analysis. A) Domain angle
vs time graph of Ig34/35. B) Distance between the functional groups in one Ig34/35
simulation. In these measurements, distances of ~5-6 Å denote the distance of a
hydrogen bond in this trace. C) Work vs. time graph of Ig34/35. D) Hierarchical
model of obscurin extending with increasing stretch. Domains first straighten,
followed by linker straightening, followed by domain unraveling.
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Figure 2-11: (Previous page) SMD simulations for each dual domain system. A)
Domain angle vs time graph of Ig34/35 (top), work vs time graph of Ig 34/35 (middle),
and distance between residues of likely interactions vs time of Ig 34/35 (bottom) for
three different SMD simulations. B) SMD data on Ig35/36, following the same
organization as (A). C) SMD data for Ig57/58. D) SMD data for Ig58/59.
Discussion
The N-terminal majority of obscurin is composed of unique Ig-like and FnIII-like
modular domains. Of the approximately 60 linkers that connect these domains, around
70% are 3-4 residues in length. Here, we study four representative short linkers. Dualdomain systems with proline-containing linkers and dual-domain systems with prolineabsent linkers are equivalently flexible in solution. Domain/domain orientation tends to
be around 160 ± 20o: almost fully extended.

MD studies suggest these multiple

orientations are of near-equivalent energies, and thus experimental high-resolution
techniques are inadequate for studying this type of multi-domain dynamic system.
Through extensive MD simulations and analyses we find, in all constructs, short linkers
facilitate specific domain/linker and domain/domain interactions.

These interactions

occur predominantly on loops and other disordered regions of the protein, and can
tolerate both moderate compression and stretch. While the exact bonds that form are
inherently unique at every interface, each construct we have studied exhibits multiple
examples of these interactions. The overarching conclusion is while short linkers facilitate
such interactions, the regions containing these bonds are sufficiently flexible to allow
significant domain motion. However there is a limit to this flexibility; when the domains
bend excessively, the surfaces begin to bump into each other thus resisting further
bending. Thus the existence of short linkers may be a mechanism in multi-domain
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proteins to avoid unwanted domain/domain clamshell formation. Conversely, when two
extended domains are pulled apart, interdomain bonds break well before the domains
themselves rupture.
Previous structural studies of a similar system in titin concluded that short linkers,
similar to those present in obscurin, lead to an extended conformation of Ig domains, and
this conformation is maintained through a series of domain/domain and domain/linker
non-covalent interactions.48 However, computational studies on these same systems
suggest that consecutive domains are flexible relative to each other.14 Thus, the idea
presented in this study, that short linkers in obscurin facilitate domain/domain and
domain/linker interactions and these interactions can tolerate domain motion, reconciles
longstanding discrepancies between experimental and computational work on the
molecular flexibility of titin.14,48
From the data gathered here, we created a simple model of how obscurin behaves
in solution (Figure 2-12). In this model, we assumed the obscurin molecule is unhindered
between the beginning and the end of its tandem Ig region (i.e. it participates in no target
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Figure 2-12: Simplified model of obscurin dynamics in solution. A) Five examples of
random-walk simulations, where the i+1 domain is allowed to bend between 0 and 45
degrees in any direction relative to the i domain. This model is of 60 domains. B) The
end-to-end distance distribution curve of 100,000 simulations, showing that the
obscurin N and C termini are most often roughly 76 nm apart from each other, given
the inputs specified.
binding in the middle of the molecule), the Ig region consists of 60 domains, each domain
is 4 nm in length, and a two-domain system bends a maximum of 45 degrees away from
180 degrees. With these inputs, one can create a random walk trajectory (for example,
see Figure 2-12A). Figure 2-12B shows a distribution curve of the distance between the
termini of this model and suggests they will be, on average, around 76 nm apart from
each other in solution. Of note, the input values can be altered, resulting in minor changes
in the average termini distance (Figure 2-13). In this model, it is worth noting that the
distance between termini range from 0 nm to ~239 nm. Given these constraints, and
given the work that others have done on similar proteins, a reasonable model of this
system is a worm-like chain model.48,51 Thus, with knowledge of the persistence length
and contour length, we can calculate the entropic energy required to completely extend
obscurin (to 239 nm), and we find this force is small: only around 28 J/mol. Further
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flexible noncovalent bonds to break in order to fully extend each linker From our SMD

Figure 2-13: Modeled average length of obscurin. A) The average obscurin length as
a function of domain angle (in degrees). The number of links = (number of domains 1) for each model. B) The average obscurin length as a function of link number. The
plots represent what angle the linkers can bend. These models were generated in the
XYZ dimensions.
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separation of the termini, up to around 270 nm (or around 5 Å per linker), requires the
flexible noncovalent bonds to break in order to fully extend each linker region. From our
SMD measurements, this extension is associated with 1-10 kJ/mol of work per linker.
This extension range is likely where obscurin behaves as a physiologically relevant
molecular spring.51 Extension past 270 nm begins unraveling individual Ig-like domains,
and requires a significant amount of work, likely in a manner reminiscent of how titin
resists overextension.17 Thus, if obscurin links two distal targets at each termini, it will
behave as a slack rope as long as those targets are less than 240 nm from each other.
As the targets separate further, obscurin begins behaving as a spring, progressively
resisting more force as the objects are moved farther apart from each other. This model
presents obvious control points to tune such a system; adding additional anchor points to
obscurin through interactions with domains in the middle of the protein, will
correspondingly reduce the chain length and create a stiffer spring. Our model is overly
simplistic; obscurin contains several regions of longer linkers (Table 2-1), and some
tandem domains may more strongly interact with each other. Additionally, parts of the
obscurin C-terminus are non-modular and other parts contain signaling domains, which
our model does not take into account. Further research in these other obscurin regions
will lead to a more refined model, and should provide more detailed insights into how
obscurin behaves in the context of the myocyte.
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Conclusions
Here we show obscurin tandem Ig-domains adopt an elongated orientation in
solution. Despite staying moderately extended, the domains have a range of flexibility.
This physical characteristic is brought about through the soft interface between
neighboring Ig domains, and the interactions this interface creates. These interactions
are postulated to help prevent self-association with neighboring domains.

As a

consequence of this elongated-yet-dynamic structure, obscurin does not significantly
resist stretching force until the inter-domain linkers, and eventually the Ig domains
themselves, begin to unravel. This hierarchical stretching profile allows for a simple
model of obscurin flexibility.

Materials and Methods

Protein Isolation
All chemicals were ACS grade or higher and were purchased from Fisher
Scientific, unless otherwise specified. Recombinant 15N, 15N-13C, and unlabeled protein
were purified after overexpression in Escherichia coli (BL21(DE3)) using pET24a vector
system (Novagen, San Diego). All constructs were induced at 37°C with 100 µM IPTG at
an OD600 = 0.6 and grown for additional 4 hours at 37°C. Cells were sonicated and
centrifuged in a small amount of buffer containing 50 mM phosphate pH 8.0,
300 mM NaCl, 10 mM imidazole and 1 mM PMSF. The resulting cleared supernatant
was passed over Ni-NTA His-bind Resin (Novagen). The column was washed
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extensively with 50 mM phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole buffer, and
eluted with the same buffer plus 500 mM imidazole. Fractions containing the protein were
then concentrated in 5000Da MWCO concentrators (Corning SpinX, Tewksburg, MA) and
applied to a Sephadex G75 (Sigma; St. Louis, MO) size exclusion chromatography
column in 50 mM Tris pH 7.5, 20 mM NaCl, 0.35 mM NaN3 (G75 buffer). Pure protein,
as determined by SDS-PAGE, was once again concentrated in a 5000Da MWCO
concentrator.

NMR
All data for NMR experiments were collected on a 600 MHz Bruker Avance II
spectrometer equipped with a TXI room temperature 5 mm probe with z axis pulse field
gradient coils. NMR samples were either collected at 10°C (for Ig 57) or 10-37°C (for all
other samples) in 20 mM Tris pH 7.5, 20 mM NaCl, 0.35 mM NaN3, and 0.3-1.0 mM
protein with 10% D2O. For Ig57, we collected a 2D HSQC and standard 15N-edited triple
resonance experiments including HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO,
C(CO)NH, HCCCONH, 15N-edited TOCSY, 15N-edited NOESY and 13C-edited NOESY,
in as previously described.44,52 For other constructs, we collected 3D HNCACB,
CBCA(CO)NH, HNCO, HN(CA)CO data along with 2D HSQCs. Most experiments were
collected with 128, 64, and 1024 points in the T1, T2, and T3 dimensions,
respectively. NMR data were processed with NMRPipe,53 extended in the indirect
dimension via linear prediction, and the resulting spectra were analyzed via Sparky.54 In
all samples, all visible HSQC backbone shifts were assigned. Chemical shifts for the
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obscurin Ig57 domain have been deposited in BMRB under the accession number
30514. Ig34, Ig35, and Ig36 chemical shift assignments were kindly provided by Dr.
Ayako Nomura (Riken Structural Biology Laboratory, Japan).

Structure Calculation
Interproton distance constraints were derived from 3D NOESY experiments (15Nedited and 13C-edited 3D NOESY) as described previously.43 Dihedral constraints y ±
20˚ and f ± 15˚ for a-helix and y ± 40˚ and f ± 40˚ for b-sheet were included based on
TALOS+ and the chemical shift index of 1Ha and 13Ca atoms.55,56 Structural calculations
were performed as described in References 23-24. Out of 200 structures, the final 20
were selected based on lowest Q-values and lowest RMSD from the average, and were
of high quality based on the statistical criteria listed in Table 2-3. The overall backbone
RMSD of ordered heavy atoms is 0.609Å. The coordinates of the human obscurin Ig57
structure have been deposited in the Protein Data Bank 6MG9.

Residual Dipolar Coupling (RDC)
Anisotropic IPAP experiments for RDC determination were performed using the
same conditions as for the HSQC with the exception of using a stretched polyacrylamide
gel.52,57 The gel was prepared using 4% acrylamide, and soaked with buffer prior to
soaking with protein. RDC values were calculated using PALES software. 58
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Small Angle X-ray Scattering (SAXS)
Different concentrations (1.0, 3.0, and 5.0 mg/mL) of various obscurin samples
were prepared in the NMR buffer. SAXS data were collected at the 12-id-B beamlines of
the Advanced Photon Source (Lemont, IL) as previously described.59 Guinier plots were
created using Origin, and the radii of gyration of the protein constructs were calculated
with the Guinier approximation.60 MultiFoXS was used to analyze the fit of SAXS and
RDC data together, as well as to back-calculate the conformation that best fit the SAXS
data.61

Molecular Dynamics (MD)
All MD simulations were performed using the YASARA 12.4.1 software package,
the Amber 03 force field, and explicit solvent (with 150 mM NaCl) in a box that extended
5 Å beyond the length of the extended construct at 37°C, and described in reference 43.
All simulations were run for at least 50 ns in triplicate.
All steered molecular dynamics simulations were performed using the PMEMD
module of the Amber 14 MD software package, using AMBERff12SB force field and in
explicit solvent.4,62–64 For equilibrium simulations, a constant temperature of 300K was
imposed using a Langevin thermostat with a collision frequency of 1 ps-1. A constant
velocity of 1.0 Å/ns (0.1 m/s) was used in order to simulate biologically relevant pulling
forces.65 The SMD spring constant (rk2) was set to 0.2 and the temperature used was
310.0 K. Analysis was visualized using Gnuplot.62
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Obscurin Modeling
A mathematical model for obscurin was created using a 4 nm rod for each domain
and nine degrees of freedom between each domain (135, 180, 225 degrees in the x, y,
and z direction, along with diagonals). Rods are connected at random in one of the nine
degrees of freedom. The total distance calculated is measure from the first rod to the
final rod. The model was implemented using MATLAB.66 The WLC formula
𝐹≈

𝑘$ 𝑇
1
1 𝑟
(
− + 4
2
𝐿' 4(1 − 𝑟/𝐿/ )
4 𝐿/

was used, where kB is the Boltzman constant, T is temperature in Kelvin, LP is the
persistence length calculated in MATLAB, r is the distance between the N and C termini
of our model, and Lc is the fully extended chain (the contour length).67
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Appendix
SAXS Analysis Tutorial and Instructions
SAXS Analysis Instructions- through Guinier analysis.
NOTE: this requires the use of Origin, which is not a free program!! However, most schools
have educational copies floating around. But just FYI: If you are doing this at home, you’ll
need to first pay for this program.
Use Origin to analyze all files
This set of instructions is to analyze SAXS data. This guide will be not showing how to collect
SAXS data, and begins with already collected data that has been mildly organized. Additionally,
this guide is written for elongated systems, but the same analysis techniques apply. If the
protein of interest is globular, only one Rg value needs to be calculated.
The files of interest should be called something like filename_all.dat and filename_av.dat
_all.dat files are all of the data for that sample
_av.dat files are the average of the data for that sample
Naming convention Example: for the data from the 1.1 mg/ml concentration of Ig3637, which
was the 93rd sample ran, we named it 3637c1p1_00093. The _all.dat file should be
3637c1p1_00093_all.dat. The _av.dat file should be 3637c1p1_av.dat. The c stands for
concentration and the p stands for “point”. Origin doesn’t work well with special characters
like periods.
1. the _all.dat files need to be looked at individually to make sure that there are no outliers.
Importing Multiple Files: Open Origin – Under the word “Image” in the tool bar, click
the icon that looks like 123 with an arrow to two speadsheets (shown below). This is called
import multiple ASCII. (We will use this button to import every file in the future). Then
navigate to where the data files are saved and open the _all.dat of 1 concentration of the
sample you want to look at. To sort only by _all.dat files and have no _av.dat files show up,
type *all* into the file name box. There should be around 3 concentrations per sample. Click
on the file, click add file, and then Ok. A Dialogue Box should open, but nothing needs to be
changed so click Ok.

The file should load into Origin. Column A is the Q value and all other columns are the actual
data. Highlight all columns except for column A by clicking on B and dragging to the end of the
sheet. Once highlighted, there is a button in the bottom left of the window that looks like a
diagonal line (shown below). Click it and a graph should open.
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The graph should look like an L or a right angle (shown below), and the scale of the axes needs
to be changed. Double click on the x axis and change the “type” from Linear to “Log10” and
change “From” from 1E-11 to 1E-3 or so. Click Apply. In the same dialogue box on the left, click
on “Vertical” to edit the Y axis. Change the “type” to “Log10” again and change “from” to
about 1E-2. Click OK. In the area of about .01 to .1 on the X axis, look to see that all of the lines
more or less take the same path (shown below). If there are any outliers that are drastically
different from the rest, find which column it is and delete it. If nothing needs to be deleted, the
_av.dat files are good to use. If something was deleted, a new _av.dat file needs to be made for
that sample.

Do this for all concentrations of each sample. Then close the origin window.
2. All of the _av.dat files for the sample need to be loaded into Origin. Only add the av files of
the same sample, but different concentrations.
Using the same method as above in a new window, add in every concentration to
Origin. Find a file, click add file, find the next concentration, add file, etc. until all
concentrations for that sample have been added. Next add the Buffer_av.dat file. To sort only
by _av.dat files and have no _all.dat files show up, type *av* into the file name box. Use the
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Buffer file that is the closest to the number on the sample files. It is ok to import more than one
buffer.
Example – if you have 3637c1p1_00093_av.dat. and you have 3 Buffer runs named
Buffer1_00085_av.dat, Buffer2_00090_av.dat, and Buffer3_00099_av.dat, load in Buffer2
because that is the buffer that was run closest to that sample.
When all files have been added, click OK. The dialogue box should open, and under “Import
Options” -> “Import Mode”, change it from “Replace Existing Data” to “Start New Columns.”
Now all of the concentrations and buffers are loaded into one window. They are not labelled,
but they are in the order that they were added, so make sure to write that down. Each file has
3 columns, so the first 3 columns are the first file you added, next 3 columns are the second file
etc. The first column of each file is the same so you only need one of them. We will keep
column A. The second column of each file is the actual data we want. The third column of each
file is the standard deviation. These third columns are also unnecessary.
To hide the unnecessary columns, highlight one starting from the first unneeded column and
holding “control” click on the other unneeded columns. Right click on one of them, Go to
Hide/Unhide Columns -> Hide. They should disappear from view. Now there should just be
Column A which is the Q values, and one column for each of the files imported. If you want to
you can name the columns by clicking in the “Long Name” yellow box. This makes it easier to
keep track of which column is which sample and concentration.
Graph the columns as before and change the scales as before.
When done, the lines should be different in the region between .01 and .1. What you should
notice is that the Buffer should be the lowest line, and the concentrations should increase from
that (shown below). Example: Buffer<c1p1<c2p3<c3p5. If the graph shows the low
concentration as higher than a higher concentration, they were either mislabeled or not
actually the labeled concentration.

3. Once the concentrations are determined, the buffer needs to be subtracted from each
concentration. From the graph, on the left side there is a small window showing the
books/graphs/tables that are in the sheet (shown below). Double click on the book and the
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table of values should appear again. More columns need to be added to do the subtractions.
To do this, click “Column” on the toolbar and then “Add new columns”. Type how many you
want to add (add enough for each sample concentration, not buffers. Ex. If you loaded 3
concentrations and 2 buffers, only add 3 new columns) and click OK.

Highlight one of the new columns, right click on it and click “Set Column Values”. A dialogue
box will pop up and here you can type a formula for every cell in the column. Pick one of the
concentrations and know which buffer needs to be subtracted from it. In the new box, type:
col(x)-.995*col(y)
where col(x) is the concentration column and col(y) is the buffer column (the column letters are
at the top of each). Click ok and the data should fill out the column. If most or all values in the
new subtraction column are positive, everything is good and can move on. If a lot of the values
are negative, get to the dialogue box again and change the .995 to something lower like .95 or
.97. You can also graph that column (changing the axes like before) and seeing when the part
of the line around .01 is relatively flat. The area to the left of this is not flat and very jagged, but
that is ok. Once the best number is found, this graph can be deleted.
Do this for each of the remaining concentrations (the .995 value can be different for each one,
as long as most of the values are positive). It might be helpful to label which column is which
concentration minus buffer.
4. Make more new columns. These columns will be used to create the Guinier plot. The
Guinier plot is the graph which gives Rg (radius of gyration) for the sample. Each concentration
will have its own Guinier, and an extra column needs to be made for the new x axis, so add n+1
columns where n is number of concentrations. Example: if there are 3 concentrations, add 4
columns.
Label the first new column Q^2 and set its value to:
col(A)*col(A)
Then click the next column and set the value to:
Ln(col(x))
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Where col(x) is the subtraction column of the concentration you want to graph.
Do this for each of the remaining columns and concentrations. It might be helpful to label
these as ln(concentration subtraction) so you know which one is which.
Highlight the Q^2 column – right click, Set As, X. This is very important and the data will not
make sense if this is not done.
Then graph one of the ln columns, but instead of using line, use Scatter which is the button next
to line (shown below). Do not change the axis types this time – it needs to be linear. Double
click on the X axis and change “from” to -.002 and change “to” to .02. This is the Guinier plot
for the chosen concentration.

5. Now that the Guinier plot has been made, the Rg values need to be calculated using the
slope of 2 portions of the graph. If the protein in the sample is globular, only find the slope of
the first region. In this experiment we knew the protein was extended, so we needed two Rg
values.
The graph should look something like this

One of the portions that you need the slope from is the area between .010 and .015. These
values can be changed, it should just be a relatively flat part on the right side of the graph. This
will give you the length in 1 dimension. This is the only region necessary for a globular protein.

51

The other portion you will need to zoom in to see. To zoom: On the very far left hand side,
there is an icon that looks like a magnifying glass with a + inside. Click on that and drag from
about .000 to .003. This zoomed in part will give you the length in another dimension. To make
the graph normal again, there is a magnifying glass under the other one with a – inside (shown
below). Click that and it should go back to normal.

The easiest way to check the slope quickly is to: Click on “Gadgets” in the toolbar, Quick Fit,
Linear. This gives a yellow box that can be moved to show the slope of the line in the box. For
a dual domain, the 1st slope should be around 50-70. The second domain slope should be
around 500-600. Don’t go below about .0001 to find slope here. Use the yellow box to find
good straight places to take the slope at.
After finding where you want to take the slope, there is a more comprehensive way which will
give the residuals of that area. To do this: On the left side where the magnifying glass is, there is
a button that looks like 2 vertical arrows that are pointing at each other called “Data Selector”
(shown below). Click this and drag the lines that appeared on the graph to the point where you
want to collect the slope. Then click “Analysis” in the toolbar, Fitting, Linear Fit, Open Dialogue,
OK. A table should appear showing the slope of the line you just made. That table can be
deleted because it now is a part of the files on the left hand side.
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To check the residuals on that line, go back to the book by double clicking on it. At the bottom
of the sheet, there should be new tabs called FitLinear1 and FitlinearCurve1. Click on FitLinear1
and at the bottom there are some graphs called “Residual Plots” – double click on this. Don’t
use the other tab. The upper left graph is the one to look at. If all of the red dots are randomly
scattered above and below the line, that data is good (shown below). If the dots seem to follow
a pattern such as a trough or a peak, the data is bad and needs to be deleted and done again. A
different area of the Guinier plot should be found that has good residuals. Right click and
delete the residual tab (you don’t have to delete this tab if you plan on using the residuals in a
figure), right click and delete the table, and right click on the line on the Guinier and delete if
necessary.

All things on the left hand side can be renamed to keep it organized by right clicking, and then
Rename. To rename the residual tab in the book, right click, then click Name and comments
and rename it that way.
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An easy naming convention is concentrationD1 and concentrationD2 to keep the dimensions
separate.
Next go back to the Guinier and zoom in to the other dimension and get the slope of that line,
same process as before.
Repeat the Guinier plot making, slope finding and residual checking for all other concentrations.
Record the slope for each dimension of each concentration.
6. After all concentrations slopes have been recorded, plug the slope into this formula:
(Sqrt(slope*3)) = Rg value
Rg value*2 = Distance
Record these values.
Repeat for any other samples.
Below is an example of a Guinier Plot. The pink areas represent where the slopes were taken.
The slope values can be seen in the tables to the left of the graph.

Basic overview of how to get to Guinier plot.
Take the data in average form of each concentration.
Subtract the buffer from the concentration
Plot this graph q vs subtraction
Take the ln of the subtraction
Plot this graph q^2 vs ln(subtraction)
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SMD Tutorial and Instructions
Steered Molecular Dynamic Simulation Instructions
make a folder: mkdir (name of folder)
enter into a folder: cd
list folders: ls
take contents of file and print to screen: cat
to move up a folder: ../
to remove a folder: rm
to make sure the simulation is running, type: top
to see how long it will take, type: cat mdinfo
copy a pdb from the computer to a supercomputer:
Open the desktop where the .pdb file is located on X11
to copy this .pdb file into the supercomputer type:
scp 3435.pdb (supercomputer IP address)
In order to set the conditions for the molecule we must use the program XLeap which will
neutralize, set parameters, and put in either explicit/implicit solvent.
This program will basically tell the atoms how to interact:
AMBER:
EXPLICIT SOLVENT
**make sure that you have removed the hydrogen atoms in the pdb file beforehand
to delete hydrogens in YASARA: Edit > delete > Hydrogens
to delete hydrogens in pymol: type- “remove hydrogens”
to open amber (this will open AMBER 12SB forcefield):
type:
xleap –x –f $AMBERHOME/dat/leap/cmd/leaprc.ff12SB
type:
model=loadpdb “Ig3536GW.pdb”
click:

> File> Load PDB File (click file and load pdb project that you want to load)

in order to neutralize, type:
charge model (this will tell you the charge)
addions model K+ (# ions: how ever many to neutralize)
addions model Clin order to put in explicit solvent, type:
solvateOct model TIP3PBOX 30.0
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in order to set parameters, type:

loadamberparams frcmod.ionsjc_tip3p
to save files that you created, type:
saveamberparm model modelname.prmtop modelname.inpcrd

FYIà inpcrd- input coordinates
input prmtop => Amberfile
inpcrd => Amber7 restart file
close AMBER by typing quit
IMPLICIT SOLVENT
to open amber (this will open AMBER 12SB forcefield):
type:
xleap –x –f $AMBERHOME/dat/leap/cmd/leaprc.ff12SB
type:
model
click:
> File> Load PDB File (click file and load pdb project that you want to load)
to set the default PBRadii mbondi3
saveamberparm model model name.prmtop modelname.inpcrd
close AMBER by typing quit
Running the Simulation
IMPLICIT SOLVENT:
to run the stretch simulation requires 3 steps:
1. Minimize structure
2. Equilibrate
3. Pull
*these files will be created in emacs:
some tips:
make sure to hit enter after the backslash
ntb=0 implies implicit solvent
igb=8 gives the forcefield you are using (ff12SB)
cut=99 which tells the program how many angstroms away each atom can see
to save in emacs: control x, control s
to exit emacs: control x, control c
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Minimization:
type:
emacs modelname.in (this is an input file)
in emacs, type:
modelname-equilibration
&cntrl
imin=1,
maxcyc=5000,
ncyc=500,
ntb =0,
igb =8,
cut =999,
/
exit emacs
the next step is to start the minimization, this requires a command:
pmemd.cuda –O –i modelname.in –o modelname.out –c modelname.inpcrd –p
modelname.prmtop –r modelname-min.rst
If you want to see the molecule in VMD:
type:
vmd modelname.prmtop
in VMD: file- new moleculeload prmtop file
file rst. file
file type: Amber 7 restart
Equilibration:
emacs modelname-equil.in
model name-equil
&cntrl
irest = 0, ntx = 1, ig=-1,
imin=0, ntb=0,
igb=8, ntpr= 1000, ntwx=1000
ntt = 3, gamma_ln = 1.0,
tempi = 0.0, temp0 = 300.0,
nstlim = 10000000, dt = 0.002,
cut =100,
ntwr = 2000,
ntc = 2, ntf = 2,
ioutfm=1,ntxo=2,
/
Save and quit
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** If you are starting equil. for the first time (for that model), irest=0 and ntx=1. If restarting
equil. irest=1 and ntx=5
emacs submit-script.sh (which has been copied into folder)
at bottom:
the next step is to start the equilibration, this requires a command:
pmemd.cuda –O –i modelname-equil.in –o modelname-equil.out –c modelname-min.rst –p
modelname.prmtop –r modelname-equil.rst –x modelname-equil.mdcrd
to see if equilibration is done:
vmd modelname.prmtop
file-new molecule
prmtop.load .mdcrd file file type: NetCDF, load all at once
Extensions- Analysis- RMSD trajectory tool
protein (whole thing) or resid # to # (certain residues)
check backbone and plot
align RMSD
Pulling or compression:
emacs modelname-equil.in
model name-equil
&cntrl
irest=1,ntx=5, ig=-1
imin=0, ntb=0
igb=8, ntpr=1000, ntwx=1000
ntt=3, gamma_ln=1.0
tempi=300.0, temp0=300.0
nstlim=100000000, dt=0.001
cut=999
jar=1
ntwr=1000
NTC=2, NtF=2
ioutfm=1, ntxo=2
/
&wt type=’DUMPFREQ’, istep=1000, /
&wt type=’END’, /
DISANG= dist.RST
DUMPAVE = dist_vs_t
LISTIN= POUT
LISTOUT=POUT
write dist.RST file:
For constant velocity:
&rst iat=___, r2=___, r2a=___, rk2=____
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iat is the two atoms which are being pulled- choose alpha carbon in VMD
r2 is the starting distance (vmd-hold 2 while clicking both atoms)
r2a is the final distane
rk2 is the spring constant
to run the simulation:
pmemd.cuda –O –i modelname-equil.in –o modelname-pull.out –c modelname-equil.rst –p
modelname.prmtop –r modelname-pull.rst –x modelname-pull.nc
EXPLICIT SOLVENT:
To run stretch simulation:
5 steps1. Optimize structure (minimize)
2. Heating calculation
3. Density- NPT
4. Equilibration (2days)
5. Pulling (3-5 days)
Scripts for each of these input files is written out below. Or copy it from an old
file.
some tips:
make sure to hit enter after the backslah
ntb=1 implies explicit solvent
igb=8 gives the forcefield you are using (ff12SB)
cut=99 which tells the program how many angstroms away each atom can see
to save in emacs: control x, control s
to exit emacs: control x, control c
3435minimization example
type emacs modelname-min.in
&cntrl
imin = 1,
maxcyc = 1000,
ncyc = 500,
ntb = 1,
cut = 10.0
/
save this file: file>save as
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pmemd.cuda –O –i modelname.in –o modelname.out –c modelname.inpcrd –p
modelname.prmtop –r modelname-min.rst &

**to make sure the simulation is running, type: top
to see how long it will take, type: cat mdinfo
3435Heating example
type emacs modelname-heat.in
3435heating
&cntrl
imin = 0,
irest = 0, ig=-1,
ntx = 1,
ntb = 1,
cut = 10.0,
ntc = 2,
ntf = 2,
tempi = 0.0,
temp0 = 300.0,
ntt = 3,
gamma_ln = 1.0,
nstlim = 10000, dt = 0.002
ntpr = 100, ntwx = 100, ntwr = -500
ioutfm=1, ntxo=2
/
pmemd.cuda -0 –i 3536heat.in –o Ig3536heat.out –c Ig3536-min.rst -p Ig3536-small3.prmtop –r
Ig3536heat.rst &
Density example
type emacs modelname-density.in
3435density
&cntrl
imin = 0, irest = 1, ntx = 5,
ntb = 2, pres0 = 1.0, ntp = 1,
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taup = 2.0,
cut = 10.0, ntr = 0,
ntc = 2, ntf = 2,
tempi = 310.0, temp0 = 310.0,
ntt = 3, gamma_ln = 1.0,
nstlim = 50000, dt = 0.002,
ntpr = 500, ntwx = 500, ntwr = 1000,
ioutfm=1,ntxo=2
ig=-1
/
pmemd.cuda -O -i Ig3536density.in -o Ig3536density.out -c Ig3536heat.rst_500 -p Ig3536small3.prmtop -r Ig3536density.rst -x Ig3536density.nc &
Equilibration example
type emacs modelname-equil.in
Ig3536-equil.in
&cntrl
imin = 0, irest = 1, ntx = 5,
ntb = 1,
cut = 8.0, ntr = 0,
ntc = 2, ntf = 2,
tempi = 310.0, temp0 = 310.0,
ntt = 3, gamma_ln = 1.0,
nstlim = 10000000, dt = 0.002,
ntpr = 2000, ntwx = 2000, ntwr = 2000,
ioutfm=1,ntxo=2,
ig=-1
/
pmemd.cuda -O -i ig3536-equil.in -o Ig3536-equil.out -c Ig3536density.rst -p Ig3536small3.prmtop -r Ig3536-equil.rst -x Ig3536-equil.mdcrd &
Pulling or compression example
First make the dist.RST file:
FOR VMD- open vmd by typing “vmd modelname.prmtop”
load files for prmtop (i.e. vmd test.prmtop)
In VMD, open the mdcrd file
Use NetCDF
Change stride to 10 and load all at once
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To run ptraj scripts, you also need this .RST file. Change the atoms you are pulling, the
distance between the atoms, and the speed of pulling:
dist.RST
&rst iat=13,2690, (this number needs to be changed)
r2=84.36, (this number needs to be changed)
r2a=184.36, (r2+100)
rk2=0.2,/
Pulling or compression:
type emacs modelname-equilibration
model name-equil
&cntrl
irest=1,ntx=5, ig=-1
imin=0, ntb=1,
igb=0, ntpr=1000, ntwx=1000
ntt=3, gamma_ln=1.0
tempi=300.0, temp0=300.0
nstlim=100000000, dt=0.002
cut=8
jar=1
ntwr=1000
NTC=2, NtF=2
ioutfm=1, ntxo=2
/
&wt type=’DUMPFREQ’, istep=1000, /
&wt type=’END’, /
DISANG= dist.RST
DUMPAVE = dist_vs_t
LISTIN= POUT
LISTOUT=POUT
To run pulling:
pmemd.cuda –O –i Ig3435equilibration –o 3435.pull.out –c 3435-small-equil.rst –p
3435-small.prmtop –r 3435-small-pull.rst –x 3435-small-pull.nc &
to analyze your data, use these ptraj scripts:
ptraj.script.distance
trajin 3435-small-pull.nc
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distance l1dist :86 :91 out l1dist.dat
distance d1dist :5 :85 out d1dist.dat
distance d2dist :92 :174 out d2dist.dat
cpptraj modelname.prmtop <ptraj.script.distance> distance.out
ptraj.script.anglestrajin 3435-small-pull.nc
angle d1d2ang :5@C,CA,N :86-92@CA,C,N :174@CA,C,N out d1d2ang.dat mass
dihedral d1d2dihed :5@C,CA,N :77@CA,C,N :106@CA,C,N :163@CA,C,N out d1d2dihed.dat
mass
cpptraj modelname.prmtop <ptraj.script.angles> angles.out
ptraj.script.interactions
trajin 3435-small-pull.nc
#Domain-linker contacts
nativecontacts :5-85 :86-91 writecontacts native-d1l1.dat resout nativeres-d1l1.dat distance 8.0
out native-d1l1.out first name native-d1l1 byresidue
nativecontacts :86-91 :92-174 writecontacts native-d2l1.dat resout nativeres-d2l1.dat distance
8.0 out native-d2l1.out first name native-d2l1 byresidue
#Domain-Domain Contacts
#quit
nativecontacts :5-85 :92-174 writecontacts native-d1d2.dat resout nativeres-d1d2.dat distance
8.0 out native-d1d2.out first name native-d1d2 byresidue
#map mapout nativemap.dat series seriesout nativeseries.dat
#run
#runanalysis lifetime native1[nonnative] out lifenative.dat nosort
cpptraj modelname.prmtop <ptraj.script.interactions> interactions.out
EMACS
Save: control x, control s
Exit: control x, control c
to get plots
gnuplot
plot ‘dist_vs_t’ u 0:4 w l
plot 'd1d2dihed.dat.mass' u 1:2 w l
etc.
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find storage things
ls -ltrh */* | grep ‘[0-9]G ‘ - lists all files more than 1 gig
ls = list
l = longform
t = timestamp
r = reverse timestamp
h = human
grep = search
*/* = all directories
du -sh directory - how the storage is used.
du = disk usage
s = search
h = human
To convert a .nc file to a .pdb file
Type emacs nc_convert.in
trajin filename.nc
strip :WAT
strip :K+
strip :Cltrajout filename.pdb
save this file
then type cpptraj filename.prmtop nc_convert.in
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